Videos

The FDA granted priority review to Dato-DXd in triple-negative breast cancer, accepted an NDA for zanzalintinib plus atezolizumab in mCRC, and more.

The FDA issued a reminder to increase awareness regarding updated capecitabine and 5-FU labels to highlight DPD deficiency risks.

Mabel Mardones, MD, discusses implications of data for Dato-DXd and sacituzumab govitecan in frontline metastatic triple-negative breast cancer.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in January 2026.

The FDA granted priority review to Dato-DXd for patients with first-line unresectable or metastatic TNBC who are not eligible to receive immunotherapy.

David Rimm, MD, PhD, discusses the strategic sequencing of ADCs in breast cancer, asserting that these agents should be classified as targeted therapies.

The American Cancer Society has released their annual Cancer Facts & Figures and Cancer Statistics reports.

Mayo Clinic Comprehensive Cancer Center is expanding surgical options for patients undergoing treatment or risk-reducing procedures for breast cancer.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, myelodysplastic syndrome, breast cancer, colorectal cancer, and cervical cancer.

Dr Jhaveri discusses the evaluation of sacituzumab govitecan earlier in the HR-positive, HER2-negative metastatic breast cancer treatment paradigm.

Breast cancer experts discuss adverse effect management when using breast cancer therapies targeting the PI3K, AKT, and mTOR pathways.

Dr Bardia discusses the ELEGANT study of elacestrant in estrogen receptor–positive, HER2-negative early breast cancer at high risk of disease recurrence.

The emergence of ultrasensitive ctDNA and CSF testing may help alter monitoring strategies and adaptive clinical trial designs in metastatic breast cancer.

The NCCN Guidelines recognize that MammaPrint can help identify a subset of early-stage breast cancer likely to benefit from anthracycline-based therapy.

The FDA accepted and gave priority review to an NDA for gedatolisib in hormone receptor–positive, HER2-negative, PIK3CA wild-type advanced breast cancer.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, breast cancer, and colorectal cancer.

Virginia Kaklamani, MD, discusses data from the ELEVATE study of elacestrant as a combination component in ER+/HER2- breast cancer.

Pumitamig/nab-paclitaxel produced responses in advanced TNBC in a phase 2 study, informing its further evaluation in the phase 3 ROSETTA Breast-01 trial.

With her collaborative ethos and patient-first focus, Lisa A. Carey, MD, ScM, FASCO, is driving innovation in breast cancer research and management.

Most premenopausal women with early breast cancer accepted GnRHa during chemotherapy to preserve ovarian function; cryopreservation uptake was lower.

A mobile health intervention was associated with improvements to general and cancer-specific quality of life in AYA breast cancer survivors.

The top 5 OncLive TV videos of the week cover insights in ALL, breast cancer, lung cancer, and pancreatic cancer.

The FDA approved subcutaneous mosunetuzumab for relapsed/refractory follicular lymphoma and granted a pair of breakthrough therapy designations.

Heather McArthur, MD, MPH, FASCO, elaborates on clinical trial data for palazestrant monotherapy in breast cancers.

Experts convene during an OncLive Peer Exchange to discuss the evolving treatment paradigm in HR-positive, HER2-negative breast cancer.

Sara Tolaney, MD, MPH, outlines emerging treatments and trials in the first-line setting for triple-negative breast cancer

Dr Mouabbi highlights the ways that ctDNA has evolved from a research tool to a potential clinical decision-making aid in breast cancer.

Phase 1 data showed that LP-184 displayed an acceptable safety profile and was well-tolerated in heavily-pretreated patients with advanced solid tumors.

On October 6, 2025, a panel of medical oncologists specializing in advanced breast cancer participated in a virtual workshop to examine the optimization of testing strategies and treatment decisions for ESR1-mutated HR+/HER2- metastatic breast cancer.

Breast oncology experts discuss SABCS 2025 data from HER2CLIMB-05 and lidERA that may influence maintenance therapy and adjuvant endocrine care.